Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Rifadin, Rimactane, Rimactan, Rifampin
Rifampicin is a semisynthetic antibiotic belonging to the rifamycin group. It exhibits bactericidal activity against a wide range of bacteria, including Mycobacterium tuberculosis, by inhibiting bacterial DNA-dependent RNA polymerase. It's primarily used in the treatment of tuberculosis and other bacterial infections.
For the treatment of tuberculosis, leprosy, and certain other bacterial infections.
Severe hepatotoxicity, including fatalities, has been reported. Rifampin should not be administered to patients with jaundice or who develop jaundice during therapy unless it is judged essential. Liver function tests should be performed before initiating therapy and frequently during treatment.
Outcome:
Increased risk of hepatotoxicity
Mechanism:
Synergistic liver damage
Outcome:
Decreased rifampicin levels
Mechanism:
CYP450 inhibition
Outcome:
Decreased rifampicin absorption
Mechanism:
Chelation
Most likely new formulation: Liposomal rifampicin for improved efficacy and reduced toxicity (Year 2025, 70% confidence)
Based on current usage trends and resistance patterns, there is a 15% likelihood of increased restrictions on rifampicin use in the next 5 years.
Antibiotic, Antitubercular
Rifamycin